Profile data is unavailable for this security.
About the company
MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2, a patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and potentially post-traumatic stress disorder (PTSD). Its oral pharmaceutical marijuana molecule, MIRA-55, is being studied for its potential to alleviate neuropathic pain, as well as anxiety and cognitive decline, symptoms commonly associated with early-stage dementia.
- Revenue in USD (TTM)0.00
- Net income in USD-12.78m
- Incorporated2020
- Employees3.00
- LocationMira Pharmaceuticals Inc1200 Brickell Avenue, Suite 1950 #1183MIAMI 33131United StatesUSA
- Phone+1 (813) 369-5150
- Websitehttps://mirapharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AIM ImmunoTech Inc | 201.00k | -28.05m | 15.27m | 26.00 | -- | 2.50 | -- | 75.95 | -0.5703 | -0.5703 | 0.004 | 0.1068 | 0.0082 | -- | 12.18 | 7,730.77 | -113.70 | -45.64 | -149.16 | -48.35 | 71.14 | -231.75 | -13,952.74 | -11,695.01 | -- | -- | 0.3018 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
| Bioxytran Inc | 0.00 | -3.51m | 15.50m | 2.00 | -- | -- | -- | -- | -0.023 | -0.023 | 0.00 | -0.0023 | 0.00 | -- | -- | -- | -2,635.88 | -1,420.53 | -- | -- | -- | -- | -- | -- | -- | -20.68 | -- | -- | -- | -- | -73.71 | -- | -- | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 15.82m | 4.00 | -- | -- | -- | 21,098.93 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Monopar Therapeutics Inc | 0.00 | -7.12m | 15.98m | 10.00 | -- | 2.62 | -- | -- | -2.31 | -2.31 | 0.00 | 1.73 | 0.00 | -- | -- | 0.00 | -81.33 | -54.07 | -102.31 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Athira Pharma Inc | 0.00 | -113.45m | 16.54m | 65.00 | -- | 0.1985 | -- | -- | -2.97 | -2.97 | 0.00 | 2.17 | 0.00 | -- | -- | 0.00 | -71.06 | -30.73 | -83.81 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Galecto Inc | 0.00 | -25.43m | 16.55m | 13.00 | -- | 0.6098 | -- | -- | -23.45 | -23.45 | 0.00 | 21.74 | 0.00 | -- | -- | 0.00 | -59.06 | -48.46 | -75.34 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
| Mira Pharmaceuticals Inc | 0.00 | -12.78m | 16.55m | 3.00 | -- | 7.46 | -- | -- | -0.8562 | -0.8562 | 0.00 | 0.1501 | 0.00 | -- | -- | 0.00 | -373.77 | -- | -737.47 | -- | -- | -- | -- | -- | -- | -3.17 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
| Evaxion Biotech A/S - ADR | 278.00k | -15.21m | 16.67m | 49.00 | -- | 12.91 | -- | 59.97 | -36.98 | -36.98 | 0.1048 | 0.2316 | 0.0174 | -- | 0.3493 | 5,673.47 | -95.08 | -100.11 | -126.11 | -131.65 | -- | -- | -5,469.42 | -131,560.30 | -- | -- | 0.8933 | -- | -- | -- | 4.51 | -- | 65.53 | -- |
| Cell Source Inc | 0.00 | -6.45m | 16.78m | -- | -- | -- | -- | -- | -0.1627 | -0.1627 | 0.00 | -0.413 | 0.00 | -- | -- | -- | -1,300.91 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -5.14 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| BioVie Inc | 0.00 | -37.18m | 16.88m | 18.00 | -- | 0.8891 | -- | -- | -9.63 | -9.63 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -94.32 | -456.35 | -149.75 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.2969 | -- | -- | -- | -92.67 | -- | -- | -- |
| Ibio Inc | 50.00k | -17.13m | 16.99m | 26.00 | -- | 0.6749 | -- | 339.77 | -13.10 | -17.09 | 0.0262 | 2.92 | 0.0011 | -- | 0.0065 | 1,923.08 | -36.24 | -28.09 | -67.39 | -32.63 | -- | -- | -34,258.00 | -1,467.30 | -- | -- | 0.3666 | -- | -100.00 | -- | 0.9764 | -- | 42.90 | -- |
| Aprea Therapeutics Inc | 1.28m | -12.93m | 17.00m | 7.00 | -- | 0.665 | -- | 13.33 | -3.03 | -3.03 | 0.2898 | 4.95 | 0.0435 | -- | -- | 182,241.40 | -44.09 | -68.66 | -50.11 | -77.19 | -- | -- | -1,013.41 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| NRX Pharmaceuticals Inc | 0.00 | -24.83m | 17.52m | 2.00 | -- | -- | -- | -- | -1.62 | -1.62 | 0.00 | -1.70 | 0.00 | -- | -- | -- | -197.97 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -189.12 | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| OpGen Inc | 1.96m | -22.39m | 17.55m | 100.00 | -- | -- | -- | 8.93 | -20.01 | -20.01 | 1.66 | -8.65 | 0.1553 | -- | 6.09 | -- | -176.99 | -87.95 | -15,455.17 | -127.65 | 3.15 | 15.42 | -1,139.66 | -794.78 | -- | -20.25 | -- | -- | 31.11 | 3.02 | 12.38 | -- | 40.20 | -- |
Data as of Sep 20 2024. Currency figures normalised to Mira Pharmaceuticals Inc's reporting currency: US Dollar USD
4.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cross Staff Investments, Inc.as of 30 Jun 2024 | 383.40k | 2.59% |
| Avantax Planning Partners, Inc.as of 30 Jun 2024 | 118.75k | 0.80% |
| Suncoast Equity Management LLCas of 30 Jun 2024 | 40.00k | 0.27% |
| HRT Financial LLCas of 31 Mar 2024 | 30.65k | 0.21% |
| Praetorian Wealth Management, Inc.as of 30 Jun 2024 | 27.50k | 0.19% |
| XTX Markets LLCas of 31 Mar 2024 | 25.54k | 0.17% |
| The Bank of New York Mellon Corp. (Investment Management)as of 30 Jun 2024 | 20.00k | 0.14% |
| First American Bank (Asset Management)as of 30 Jun 2024 | 20.00k | 0.14% |
| G1 Execution Services LLCas of 31 Mar 2024 | 15.57k | 0.11% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 10.23k | 0.07% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
